Journal of the National Cancer Institute Advance Access originally published online on February 26, 2008
JNCI Journal of the National Cancer Institute 2008 100(5):373; doi:10.1093/jnci/djn012
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author 2008. Published by Oxford University Press.
CORRESPONDENCE |
Re: When You Look Matters: The Effect of Assessment Schedule on Progression-Free Survival
Affiliations of authors: Dana-Farber Cancer Institute, Boston, MA (PGR, KCA); Weill Medical College of Cornell University, New York Presbyterian Hospital, New York (RN); Hospital Clinic of Barcelona, Barcelona, Spain (JB)
Correspondence to: Paul G. Richardson, MD, Dana-Farber Cancer Institute, 44 Binney Street, Dana 1B02, Boston, MA 02115 (e-mail: paul_richardson@dfci.harvard.edu).
| The first 10% of the full text of this article appears below. |
Panageas et al. (1) recently showed that progression-free survival (PFS) is dependent on the assessment schedule; the same is true of time to progression (TTP). Other factors that may affect TTP include: 1) whether it is measured from diagnosis, randomization, or first dose; 2) whether progression is defined by investigator assessment or a
Article about this Correspondence
Related Article in JNCI
![]()
CiteULike
Connotea
Del.icio.us What's this?
J Natl Cancer Inst 2007 99: 428-432.
J Natl Cancer Inst 2007 99: 428-432.
This article has been cited by other articles:
![]() |
J. F. San Miguel, R. Schlag, N. K. Khuageva, M. A. Dimopoulos, O. Shpilberg, M. Kropff, I. Spicka, M. T. Petrucci, A. Palumbo, O. S. Samoilova, et al. Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma N. Engl. J. Med., August 28, 2008; 359(9): 906 - 917. [Abstract] [Full Text] [PDF] |
||||
